Increasing evidence suggests heterogeneity in the molecular pathogenesis of cystic fibrosis (CF). Mutations such as deletion of phenylalanine at position 508 (AF508) within the cystic fibrosis transmembrane conductance regulator (CFTR), for example, appear to cause disease by abrogating normal biosynthetic processing, a mechanism which results in retention and degradation of the mutant protein within the endoplasmic reticulum. Other mutations, such as the relatively common glycine -, aspartic acid replacement at CFTR position 551 (G551D) appear to be normally processed, and therefore must cause disease through some other mechanism. Because AF508 and G551D both occur within a predicted nucleotide binding domain (NBD) of the CFTR, we tested the influence of these mutations on nucleotide binding by the protein. We found that G551D and the corresponding mutation in the CFTR second nucleotide binding domain, G1349D, led to decreased nucleotide binding by CFTR NBDs, while the AF508 mutation did not alter nucleotide binding. These results implicate defective ATP binding as contributing to the pathogenic mechanism of a relatively common mutation leading to CF, and suggest that structural integrity of a highly conserved region present in over 30 prokaryotic and eukaryotic nucleotide binding domains may be critical for normal nucleotide binding. (J. Clin. Invest. 1994. 94:228-236.)
Introduction
Many of the mutations which cause clinical cystic fibrosis (CF)l occur within the two nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR) (1) (2) (3) . While the precise role of the nucleotide binding domains (NBDs) in CFTR function is still unknown, previous studies have shown that the anion channel function of CFTR is dependent upon the presence of ATP or other nucleotides (4) (5) (6) (7) (8) . Studies in our laboratory (9) as well as by others (10, 11 ) have suggested that AF508, the most common mutation associated with clinical CF, is not associated with disrupted nucleotide binding by folded CFJlR polypeptides. Phenylalanine 508 is not highly conserved among the NBDs of more than 30 prokaryotic and eukaryotic members of the ATP binding cassette (ABC) gene family which includes CFTR (1, 12, 13) ; this observation has suggested that the F508 residue might not directly contribute to ATP binding by CFTR. In addition, increasing evidence suggests that CFTR possessing the AF508 mutation is improperly processed within epithelial cells, and that disease results because the mutant protein fails to insert properly in the apical cell membrane (14) (15) (16) (17) . Such a pathogenic mechanism is not likely to be dependent upon ATP binding by the NBD.
The second most common mutation leading to clinical cystic fibrosis is a glycine to aspartic acid replacement within NBD-1 at CFTR position 551 (G551D) (2, 18, 19) . Because (a) both G551D and the corresponding mutation in NBD-2, G1349D, cause clinical CF; (b) both mutations involve a glycine residue which is invariant in alignments of > 30 nucleotide binding domains from the ATP binding cassette gene family (1, 12, 13) ; (c) chloride channel studies from heterologous eukaryotic cells expressing recombinant CFTR have raised the possibility of a defective response to ATP by CFTR with these mutations (5); and (d) both G551D and G1349D appear to be normally processed to the cell membrane, (5, 14, 15) , we tested the influence of these mutations on nucleotide binding by CFTR NBDs. We found that G551D and G1349D, but not AF508, significantly decreased nucleotide binding by recombinant NBDs. These annealing, and 3 min x 72°C elongation. Primers were chosen to create EcoRI sites at the ends of PCR products to allow cloning into the EcoRI site of pGEX 2T (Pharmacia Fine Chemicals, Piscataway, NJ) in frame with glutathione-s-transferase (GST) and immediately 3' to an engineered thrombin cleavage site (9) . All PCR products obtained by this method were of the predicted size (524-bp NBD-1, 545-bp NBD-2). In addition, identity of correct recombinants were verified by (a) restriction mapping using [10] [11] [12] digests per recombinant construct; (b) re-amplification of the full length NBD insert using the recombinant plasmid as template; (c) recombinant plasmid-directed synthesis of fusion protein and specific cleavage by human thrombin into the two predicted fragments; and (d) amino-terminal sequencing and compositional analysis (13 amino-terminal residues of NBD-1 and 12 amino-terminal residues of NBD-2, as well as > 30 internal residues obtained during peptide mapping matched the predicted sequence of the recombinant proteins). Recombinant fusion protein was collected and partially purified as an inclusion body preparation as described previously (9) . After thrombin treatment (in a protease cleavage buffer containing 50 GST, some uncleaved fusion protein and minor bacterial contaminants) was applied to the top of a preparative acrylamide gel (Bio Rad Laboratories) and the NBD purified using electrophoresis through 12% acrylamide as in Fig. 1 (10, 11) . Adenine nucleotide fluorescence was measured at each data point for 1 s in a 1-ml quartz cuvette using a Perkin Elmer LS-50 spectrofluorometer (Perkin-Elmer Corp., Norwalk, CT) with excitation 408 nM and emission 538 nM. y32p-2-azido ATP labeling ofNBDs. 2-azido ATP was synthesized from 2 azido AMP (20) by the method of Michelson as modified by Salvucci et al. (21) . [y-32p]2-azido ATP (sp. act. 5-35 mCi/,.mol) was then prepared and purified as described previously (22 (23) . Gels were then stained, fixed, and labeling quantified on an AMBIS 4000 Imaging System (Ambis, Inc., San Diego, CA).
Results
We used prokaryotic over-expression to generate quantities of CFTlR NBDs sufficient for binding and structural studies ( Concentration (,uM) obtain a refolding sequence relevant to the native CFTR structure and function. First, we have previously shown that recombinant wild-type and AF508 CFTR NBD-1 derived from bacteria bind ATP affinity agarose as well as 32p-8-azido ATP (9) . The data presented below indicates that two additional ATP analogs, trinitrophenyl ATP and 32p-2-azido ATP, also bind the recombinant NBD. All four ligands can be displaced by Na2 ATP with half maximal displacement occurring at -5 mM ATP. (9, E. J. Sorscher and J. Logan, unpublished observations). Second, the proteins generated for these studies display substantial secondary structural content (-70% ,3 sheet, 10% a helix) when studied by circular dichroism, a result in agreement with a high ,/ sheet content reported for a synthetic peptide corresponding to a 67 amino acid segment of the NBD-1 (10). Third, although in vitro studies of recombinant CFTR using cell free membrane patches have demonstrated half maximal ATP stimulation at -270 jIM (4) , the ATP binding affinity constants which we have observed for NBD-1 are very similar to those reported for CFTR Cl -conductance reported in both native, perfused human sweat ducts and in a non-recombinant human cell line expressing high levels of CFTR (T84) (7, 24 ; see also 8). Half maximal CFTR activity in both systems was reported at 3-5 mM, a finding which suggested that cellular ATP levels may represent an important regulatory constraint on CFTR anion channel activity. These observations indicate that the nucleotide binding domains used in our studies possess substantial structure after refolding and bind ATP with an affinity very similar to that observed in macroscopic measurements of full length CFTR Cl-conductance. We used two independent assays of nucleotide binding to test the significance of the AF508 and G551D mutations (Fig.  2) . NBD-1 containing the AF508 mutation demonstrated very similar binding to the wild type NBD-1 as measured using either TNP-ATP or 32p-2-azido ATP. This result is consistent with previous studies in our laboratory using other measurements of nucleotide affinity (9) , as well as with conclusions reached using fully folded synthetic peptides corresponding to portions of the CFTR NBD-1 with and without F508 (11) , and with a computer-based model of the NBD derived from a secondary structural alignment containing the known two-and three-dimensional structure of adenylate kinase (12, see below). In contrast, as shown in Fig. 2 A, the G551D mutation inhibited (27) .
Our estimated binding affinity for ATP agrees closely with our previously reported estimates of ATP affinity for the NBD (9), with macroscipic measurements of the ATP dependence of CFTR Cl channel activity using two independent systems (7, 24) and reasonably well with displacement of TNP-ATP from a maltose binding protein/NBD-l fusion protein (28) , and with displacement of 32p-2 azido ATP from the full length CFTR (29) (Fig. 2 A) , where GSSlD saturates at 8-10 Mm TNP-ATP, and saturation for the wild-type and the AFS08 NBD occurred at significantly higher concentrations.
This results suggests that in addition to physically disrupting the nucleotide binding pocket within the nucleotide binding site (see Discussion), the G --D replacement at position 551 might also destabilize overall protein folding in such a way as to create an equilibrium between NBD folded and unfolded forms. The result would be an apparent decrease in measurable binding sites within the NBD preparation and would explain the lower ligand concentration at saturation for GSS1D described in Fig.  2 A. Ultraviolet spectral analysis of the structures of wild-type and mutant NBDs in the presence and absence of nucleotides, and in the presence of denaturants such as urea (9, 11 ) are in progress to evaluate effects on protein folding stability mediated by GSSlD. To confirm that less nucleotide was actually bound to CFTR polypeptides containing the GSSlD mutation, we performed an additional series of experiments using an independent nucleotide binding assay. As shown in Fig. 2, B (Fig. 2 A) , and a diminished half maximal binding in experiments using the 32p-2 azido ATP (Fig. 2 B) . Such an observation could be explained by a change in nucleotide binding pocket hydrophobicity (causing a decreased fluorescence signal from TNP-ATP even at maximal occupancy) together with loss of one of a small number of sites normally available for covalent photolabeling by 32p-2-azido ATP (an abnormality with might be overcome at increasing concentrations of photoaffinity ligand).
Although the glycine corresponding to G551 is invariant among more than 30 ABC proteins (and an even larger numbers of NBDs, since each ABC protein possesses 2 NBDs), the functional significance of this glycine residue and the immediately adjacent, highly conserved residues found within all members of the gene family is not known (Other members of the gene family, for example, include the human multidrug resistance gene (MDR), the chloroquine resistance gene product of P. malaria, and the recently described human adrenoleukodystrophy gene [1, 12, 13, [31] [32] [33] [34] ). An LSGGQQXQR motif is highly conserved across the ABC gene family (glycine corresponding to G551 underlined) (1, 12, 13), but is not present in other nucleotide binding proteins such as adenylate kinase, for example, or included within the so-called Walker A or Walker B sequences characterizing a broad range of non-ABC family, ATP-binding proteins (35, 36) . It has been proposed that in the histidine permease of S. typhimurium (an ABC protein), the residues near the LSG(JQXQR motif could serve as a "linker peptide" which conveys conformational changes between segments of the domain (37) .
To further test our hypothesis that this conserved region functions in nucleotide binding, we generated additional recombinant proteins corresponding to the wild-type CFTR NBD-2 and to NBD-2 containing a G1349D mutation (i.e., a mutation in NBD-2 which causes clinical CF and occurs at the glycine residue in NBD-2 which aligns with G551 in NBD-1). As shown in Fig. 3, G1349D disrupts binding The magnitude of 32p-2 azido ATP labeling is highly dependent upon the specific activity of the photoaffinity ligand used. The specific activity of 32p-2 azido ATP used in Fig.  3 B was 10-fold higher than that used in Fig. 2 B. When wild-type NBD-1 and NBD-2 were directly compared using photolabeling under identical conditions (and using the same lot of 32p-2 azido ATP), a -10-fold enhancement of maximal photolabeling was observed in NBD-2 compared with NBD-1 (data not shown).
TNP-ATP were 8.9 fluorescence units (wild-type NBD-2) and 3.5 fluorescence units (G1349D NBD-2); half-maximal binding was observed at 3.8 and 5.3 gcm TNP-ATP for the wt NBD-2 and G1349D mutants, respectively. Half-maximal photoinsertion of the wild type NBD-2 with 32p-2 azido ATP was observed at a ligand concentration of -13 um, whereas photolabeling was substantially less for the G1349D compared with the wild-type NBD-2 at every ligand concentration studied. These findings have significance, since they suggest a general function of the conserved glycine and surrounding residues may be in nucleotide binding. The results are consistent both with previous observations indicating an abnormal ATP dependence in CFTR containing mutations in this glycine residue (5) (18, 39) .
Discussion
To test the influence of CF mutations on nucleotide binding, we constructed and purified the CFTR domains which have been implicated as both necessary and sufficient for nucleotide interactions with CFTR (1-5, 9-13). The highly conserved, functionally independent and even interchangeable nature of CFTR and other nucleotide binding domains (which span -200 amino acids and share 30% amino acid identity throughout the ABC gene family) suggests that one approach to understanding the molecular pathogenesis of CFTR mutations might focus on the domains themselves, as opposed to any particular ATP binding cassette protein context. For example, the NBDs in the LIV-I neutral branched chain amino acid transport system of E. coli and the histidine permease of S. typhimurium are found on genes separate from the remainder of the transport complex (and are therefore synthesized separately), but assemble with the remainder of the ABC complex at the cell membrane. When CFTR NBD mutations were placed at corresponding residues within these bacterial NBDs, (or within the NBDs of the yeast mating factor transporter, STE 6), certain of these mutations had functional effects consistent with those observed in CFTR (although others did not. See refs. 37, 38, 40) . Furthermore, in ABC proteins containing both NBDs within a single polypeptide chain, the two NBDs can be separated and still maintain function. For example, when the STE 6 cDNA, which codes for both NBDs of the protein, was severed into two halves, (each of which contained one of the NBDs), coexpression of the two STE 6 truncations led to functional reconstitution of STE 6 mediated a-factor transport (40) .
NBDs are also interchangeable among members of the ABC protein family. The NBD-1 of CFTR, for example, can be grafted into STE 6 in place of the STE 6 NBD-1 to allow 232
Logan et al. Although the anion channel activity of wild-type and mutant CFTR polypeptides has become the most useful endpoint defining normal CFTR function, mutations which cause clinical CF in many cases cause only small alterations in channel activity in vitro. For example, in a series of four NBD-1 and NBD-2 mutations which cause disease (including G1349D and GSS1S), although 4-8-fold differences in open probability were observed in vitro when compared with wild type, no abnormalities in maximal single channel currents could be documented (although small differences in the dependence of current on ATP were observed for the mutants) (5) . In vivo, potential difference measurements in respiratory epithelia of CF patients differ by less than threefold compared with normal controls (47, 48) . This data further supports the notion that even subtle changes in normal CFTR function may have important physiologic consequences. Finally, measurements of CFTR activity in intact human tissues and cell monolayers have indicated that half maximal CFTR activation requires maximal cellular ATP levels (-5 mM), and that CFTR activity may be coupled to physiologic nucleotide levels within the cell (7, 24) . The decrease in binding of ATP analogs demonstrated here has significance, therefore, since a similar defect in nucleotide binding in vivo could result in mutant CFTR which would be activated only at nucleotide levels which are not present within the cell.
Our studies using recombinant CFTR NBDs provide a test of recent predictions concerning the function and structure of NBDs within the ABC gene family. For example, based upon Michaels-Menten analyses of the ATP dependence of CFTR anion channel open probability, it has been proposed both that the full length CFTR contains only one functional ATP binding site (30) , and that two active nucleotide binding sites are present within the full length molecule (5 In an attempt to relate NBD tertiary structural models to our findings concerning nucleotide binding, assignment of the corresponding locations of these residues within the known adenylate kinase tertiary structure was performed.
As shown in Fig. 4 , assignment of the positions of G551 and G1349 is straightforward based on previously determined alignments (12) . These residues would be predicted to fall immediately after the third /8 strand in both the adenylate kinase and the predicted CFTR Figure 4 . Positions of residues G551 and G1349 in a tertiary structural model of the NBD based on adenylate kinase. The similarities between predicted secondary structure of ABC protein NBDs and the known structure of adenylate kinase, together with the structural similarities of nucleotide binding sites within diverse, unrelated proteins outside of the ABC family (e.g., between adenylate kinase, the elongation factor Tu and p21 ras), suggest that the tertiary structure of nucleotide binding sites in the NBDs of CFI7R and other ABC family members may closely resemble those of adenylate kinase (12, 13, 35) . In an attempt to relate previous tertiary structural models of CFTR to our findings of defective nucleotide binding by the G551D and G1349D NBDs, we predicted the location of these residues based on previous alignments of CFTR NBDs with adenylate kinase. As shown in the Figure,  G551 and G1349 occur in a loop immediately following the third /s strand of both the adenylate kinase and the CFTR NBD models (49, 50; the prediction also conforms to the CFTR NBD model of ref. 12). The Walker A sequence is part of a connecting loop between the first /3 strand and an a helix. Both the Walker A motif and the residues at G551 or G1349 are predicted to fall within a large cleft suitable for nucleotide binding; this cleft is known both by NMR and x-ray crystallography to bind AMP within the adenylate kinase molecule. The two views above are -900 rotated from each other; the /3 strands are green, a helices are blue, and the loops are white. The Walker A site and the location of G551 or G1349 are shown in red. A ball and stick model of AMP is shown in a nucleotide binding site. The atoms are colored according to the following code: N, blue, 0, red, C, green, P. yellow. The figure was prepared using the program Ribbon 2.0 (51).
nylate kinase (49, 50) , as shown in Fig. 4 , G551 and G1349 are on the wall of a cleft suitable for ATP binding within the NBD. Another wall of the cleft is formed by the so-called ploop or Walker A motif (GXXXXGKT/S) which is (a) present in nearly all ATP binding proteins, (b) known to contain residues which actually coordinate with phosphate groups of ATP (such as the p-loop lysine within p21 ras), and (c) highly likely to be involved in ATP binding by the CFTR and other NBDs, since the conservation of this motif is invariant through the ABC gene family (1, 12, 35, 36) . Recent data from our laboratories has also shown that a peptide containing residues 1335 to 1351 is covalently labeled in the intact NBD-2 by 32p-2-azido ATP, suggesting the proximity of this region to the ATP binding site within the NBD. Thus our findings of diminished nucleotide binding mediated by G551D and 
